@ecoool2
Good to see you back my friend.
Mesoblast has more than enough data on remestemcel-l and the modulatory mechanism on the immune system and inflammation. I say this because the way I read the announcement no where does it say the need for a trial. I could be wrong obviously, but I think this is more of a case of how do e make this work and who do we partner with to ramp up. I agree this isn't something chief medical advisors will sit on. It's days away IMO.
it a trial may not be needed and if
@ecoool2 Good to see you back my friend. Mesoblast has more than...
-
- There are more pages in this discussion • 19,685 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.21 |
Change
0.040(3.42%) |
Mkt cap ! $1.381B | |||
| Open | High | Low | Value | Volume |
| $1.17 | $1.22 | $1.17 | $5.683M | 4.776M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20000 | $1.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.21 | 19746 | 3 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |